ClinicalTrials.gg
CompletedNCT02626026Updated Sep 9, 2020Results posted

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

A Phase 1 interventional study of Tirabrutinib and Placebo in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Rheumatoid by Gilead Sciences — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Gilead Sciences.

Enrollment
7th of 12
42 · median 49
Started
2016
with 5 others
Phase 1
6 of 12
none open now
Registered
2nd of 12
by date

Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one is the 7th largest by enrollment, is one of 6 that started in 2016, is one of 6 in phase 1, and was the 2nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 12 studies in Arthritis, Rheumatoid by Gilead Sciences is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Arthritis, Rheumatoid by Gilead Sciences as a file.
02

Study summary

This study will consist of two parts: Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirabrutinib in healthy participants. Part B will evaluate the safety, tolerability, and the effect of tirabrutinib on disease-specific clinical markers and outcomes in participants with rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A

  • Be a nonsmoker
  • Have a calculated (BMI) from 19 to 30 kg/m\^2, inclusive, at screening
  • Have a (CrCl) ≥ 90 mL/min (using the Cockcroft-Gault method based on serum creatinine and actual body weight as measured at screening
  • Females of must have a negative serum pregnancy test at screening and clinic admission.
  • Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of
  • Must, in the opinion of the investigator, be in good health based upon medical history and physical examination, including vital signs
  • Screening laboratory evaluations (hematology including reticulocytes, fasting lipids, chemistry, and urinalysis) must fall within the normal range of the local laboratory's reference ranges unless the results have been determined by the investigator to have no clinical significance
  • Have either a normal 12-lead or one with abnormalities that are considered clinically insignificant by the investigator in consultation with the Sponsor

Part B

  • Diagnosis of RA (according to the 1987 American College of Rheumatology (ACR) classification criteria OR a score of ≥ 6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA)
  • Individuals must have taken methotrexate (MTX) 7.5 to 25 mg/week continuously for at least 12 weeks, with at least 6 weeks of stable dose prior to first study drug dose and throughout study duration.
  • Individuals must be receiving folic or folinic acid supplementation at a stable dose for at least 6 weeks prior to Day 1 dosing and throughout study duration
  • Individuals are allowed to remain on anti-malarial therapy, with at least 8 weeks of stable dose prior to first study drug dose
  • Use of oral of no more than 10 mg prednisone or its equivalent per day is allowed if dose is stable for at least 28 days prior to first study drug dose
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesics (including aspirin ≤ 100 mg daily) are allowed if doses are stable for at least 14 days prior to the first dose of study drug
  • Estimated creatinine clearance (CLCr) ≥ 60 mL/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at the screening evaluation
  • White blood cells (WBC), , lymphocyte count, and count ≥ 0.75 x lower limit of normal (LLN)
  • A negative serum pregnancy test at screening and a negative pregnancy test on the Day 1 visit prior to the first dose of study drug for female individual of child bearing potential.
  • Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception

Exclusion criteria

Exclusion Criteria

Part A

  • Pregnant or lactating individuals
  • Have any serious or active medical or psychiatric illness (including depression) which, in the opinion of the Investigator, would interfere with individual's treatment, assessment, or compliance with the protocol. This would include renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or that are or requiring treatment
  • Positive test for drugs of abuse, including alcohol at screening or on Day -1/check-in
  • A positive test result for (HIV-1) antibody, (HBV) surface antigen or (HCV) antibody
  • Have poor venous access that limits phlebotomy
  • Have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins and/or acetaminophen and/or hormonal medications
  • Have been treated with systemic , therapies, or chemotherapeutic agents within 3 months prior to Screening or expected to receive these agents during the study (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)
  • Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)
  • Medical or surgical treatment that permanently alters gastric absorption (eg, gastric or intestinal surgery); a history of cholecystectomy is not exclusionary

Part B

  • Known to formulation .
  • Pregnant or lactating females
  • Previous treatment with B-cell depleting agents (eg, rituximab) within 12 months of treatment
  • Prior treatment with any commercially available or Bruton's tyrosine kinase (BTK) inhibitor
  • Diagnosis of diabetes, history of impaired glucose tolerance test, history of abnormal (HbA1c), or history of impaired fasting glucose
  • Current treatment with any other disease modifying anti-rheumatic drug (DMARD) other than MTX and hydroxychloroquine, unless appropriate wash out
  • Current treatment with any biologic agent, unless appropriate wash out
  • Any laboratory abnormality or condition that, in the investigator's opinion, could adversely affect the safety of the individual or impair the assessment of study results
  • History of or current inflammatory joint disease, other than RA
  • Active significant systemic involvement secondary to RA such as vasculitis, pulmonary fibrosis or Felty's syndrome
  • History of or current or rheumatic disorders, other than RA
  • RA functional class 4 or other uncontrolled medical conditions
  • History of ongoing, chronic or recurrent infections or recent serious or life-threatening infection
  • Presence of any condition that could, in the opinion of the investigator, compromise the individual's ability to participate in the study, such as history of substance abuse, alcoholism, or a psychiatric condition
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Cohort 1, Part A: Tirabrutinib 20 mg QD

    Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.

    Drug: Tirabrutinib

  • Placebo comparator
    Cohort 1, Part A: Placebo

    Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.

    Drug: Placebo

  • Experimental
    Cohort 2, Part A: Tirabrutinib 10 mg BID

    Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.

    Drug: Tirabrutinib

  • Placebo comparator
    Cohort 2, Part A: Placebo

    Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.

    Drug: Placebo

  • Experimental
    Part B: Tirabrutinib 20 mg QD

    Tirabrutinib 20 mg capsules orally QD for 4 weeks.

    Drug: Tirabrutinib

  • Placebo comparator
    Part B: Placebo

    Placebo to match tirabrutinib capsules orally QD for 4 weeks.

    Drug: Placebo

Interventions

  • Capsules administered orally.

    Also known as: GS-4059

  • DrugPlacebo

    Capsules administered orally.

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to last dose (maximum: 7 days) plus 30 days

  2. Part A: Percentage of Participants With Treatment-Emergent Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment after the first dose of study drug and within 30 days after last study drug administration. Laboratory abnormalities without clinical significance were not recorded as AEs or serious AEs. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = potentially life threatening.

    Time frame: First dose date up to last dose (maximum: 7 days) plus 30 days

  3. Part A: Percentage of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities

    Time frame: First dose date up to last dose (maximum: 7 days) plus 30 days

  4. Part A: Cmax: Maximum Observed Plasma Concentration of Tirabrutinib

    Cmax is maximum observed concentration of drug in plasma.

    Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose

  5. Part A: Clast: Last Observed Quantifiable Plasma Concentration of Tirabrutinib

    Clast is the last observed concentration of drug in plasma.

    Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose

  6. Part A: Tmax: Time (Observed Time Point) of Cmax of Tirabrutinib

    Tmax is the time observed for the Cmax of tirabrutinib.

    Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose

  7. Part A: Tlast: Time (Observed Time Point) of Clast of Tirabrutinib

    Tlast is the time observed for the Clast of tirabrutinib.

    Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose

  8. Part A: AUCtau: Area Under the Plasma Concentration (AUC) Versus Time Curve Over the Dosing Interval of Tirabrutinib

    AUC is concentration of drug over time (area under the plasma concentration versus time curve).

    Time frame: Cohorts 1 and 2, Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose relative to the morning dose

  9. Part A: AUClast: AUC Versus Time Curve From Time Zero to the Last Quantifiable Concentration of Tirabrutinib

    AUC is concentration of drug over time (area under the plasma concentration versus time curve).

    Time frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose

  10. Part B: Percentage of Participants Who Experienced TEAEs

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or Any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date up to last dose (maximum: 29 days) plus 30 days

  11. Part B: Percentage of Participants With Treatment-Emergent Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment after the first dose of study drug and within 30 days after last study drug administration. Laboratory abnormalities without clinical significance were not recorded as AEs or serious AEs. Treatment-emergent laboratory abnormalities were graded per CTCAE, version 4.03 where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = potentially life threatening.

    Time frame: First dose date up to last dose (maximum: 29 days) plus 30 days

  12. Part B: Percentage of Participants With 12-Lead ECG Abnormalities

    Time frame: First dose date up to last dose (maximum: 29 days) plus 30 days

Secondary outcomes

  1. Part A: Change From Baseline in Percent Inhibition of CD63 Basophils at Days 1, 3, 5 and 7

    The effect of tirabrutinib on biomarkers was assessed through the CD63 basophil activation test (BAT) FlowCast assay, which was used to measure the percentage of CD63+ basophils and percentage inhibition of CD63 induction relative to baseline. CD63+ % inhibition was calculated as 100 - CD63+ % baseline. Baseline defined as day 1 predose.

    Time frame: Days 1 and 7: Predose and 2, 6, 12, 24 hours postdose; Days 3 and 5: Predose and 2 hours postdose

  2. Part A: Change From Baseline in Percent Bruton's Tyrosine Kinase (BTK) Occupancy at Days 1, 3, 5 and 7

    BTK occupancy was assessed with the BTK occupancy assay, which was used to measure undetectable free BTK, normalized free BTK, normalized free BTK adjusted to baseline, and percentage BTK occupancy adjusted to baseline. % BTK occupancy adjusted was calculated as 100 \* (1 - normalized free BTK adjusted to baseline). Normalized free BTK was calculated as Free BTK / Total BTK. Baseline defined as day 1 predose.

    Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose; Days 3 and 5: Predose and 2 hours postdose; Day 7: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, 120 hours postdose

  3. Part B: Change From Baseline in Disease Activity Score for 28 Joint Counts (DAS28) Using C-Reactive Protein (CRP) at Weeks 2, 4 and Posttreatment Week 4

    DAS28 score was used to measure the participant's disease activity or assessments of rheumatoid arthritis (RA) calculated using the tender joint counts (TJC) (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (PtGA) (visual analog scale: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4

  4. Part B: Change From Baseline in Individual American College of Rheumatology (ACR) Component: Tender Joint Count (TJC) Based on 68 Joints (TJC68) at Weeks 2, 4 and Posttreatment Week 4

    ACR TJC was an assessment of 68 joints. At each study visit, a joint evaluator assessed whether a particular joint was "tender" where presence of tenderness was scored as "1" and the absence of tenderness was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons. It was derived as the sum of all tender joints. The range for TJC68 was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4

  5. Part B: Change From Baseline in Individual ACR Component: Swollen Joint Count (SJC) Based on 66 Joints (SJC66) at Weeks 2, 4 and Posttreatment Week 4

    ACR SJC was an assessment of 66 joints. At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons. It was derived as the sum of all swollen joints. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week

  6. Part B: Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4 and Posttreatment Week 4

    SDAI is a composite measure that sums the TJC based on 28 joints (TJC28), SJC based on 28 joints (SJC28), PtGA, Physician's Global Assessment of Disease Activity (PhGA), and the CRP (in mg/dL). PtGA and PhGA assessed using Visual Analogue Scale (VAS) on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4

  7. Part B: Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4 and Posttreatment Week 4

    CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4

  8. Part B: Change From Baseline in Individual ACR Component: Patient's Global Assessment of Disease Activity (PtGA) at Weeks 2, 4 and Posttreatment Week 4

    PtGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A horizontal visual analog scale was used to provide the patient's overall assessment of how the arthritis is doing. A mark was placed on the horizontal line to assess the current arthritis disease activity. The lowest mark indicated 'no arthritis activity', and the highest mark indicated 'extremely active arthritis'. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4

  9. Part B: Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PhGA) at Weeks 2, 4 and Posttreatment Week 4

    PhGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A horizontal visual analog scale was used to measure the physician's assessment of the patient's current disease activity. A mark was placed on the horizontal line to assess the disease activity (independent of the participant's self-assessment). The lowest mark indicated 'no disease activity', and the highest mark indicated 'maximum disease activity'. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4

  10. Part B: Change From Baseline in Individual ACR Component: Patient's Global Assessment of Pain at Weeks 2, 4 and Posttreatment Week 4

    The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A horizontal visual analog scale was used to assess the patient's current level of pain. A mark was placed on the horizontal line to assess the severity of pain. The lowest mark indicated 'no pain', and the highest mark indicated 'unbearable pain'. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4

  11. Part B: Change From Baseline in the Health Assessment Questionnaire Disability Subscales (HAQ-DI) Score at Weeks 2, 4 and Posttreatment Week 4

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually administered by the participant. Responses in each functional category were collected as 0-3 \[0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4 and Posttreatment Week 4

  12. Part B: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Weeks 2, 4 and Posttreatment Week 4

    ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PhGA and PtGA assessed using VAS on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity); patient's pain assessment using VAS on a scale of 0-100 (0 indicating no pain and 100 indicating unbearable pain); HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 (0 and 3 indicating without difficulty and unable to do); high-sensitivity CRP (hsCRP).

    Time frame: Weeks 2, 4 and Posttreatment Week 4

  13. Part B: Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) Response at Weeks 2, 4 and Posttreatment Week 4

    ACR70 response is achieved when the participant has: ≥ 70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PhGA and PtGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; patient's pain assessment using VAS on a scale of 0-100 \[0 indicating no pain and 100 indicating unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP.

    Time frame: Weeks 2, 4 and Posttreatment Week 4

  14. Part B: Hybrid ACR Improvement Response at Weeks 2, 4 and Posttreatment Week 4

    Hybrid ACR evaluates the improvement in active RA by combining elements of the ACR20, ACR50, and ACR70 with a continuous score of the mean change in core set measures. The percentage improvement from baseline was computed in each of the components of the ACR. The average percent improvement was calculated and used with the participant's ACR20, ACR50, and ACR70 status to compute the hybrid ACR response, with a positive change indicating improvement.

    Time frame: Weeks 2, 4 and Posttreatment Week 4

  15. Part B: Percentage of Participants Who Achieved Remission as Measured by DAS28-CRP at Weeks 2, 4 and Posttreatment Week 4

    Clinical remission is defined as DAS28-CRP \< 2.6. DAS28 score was used to measure the participant's disease activity or assessments of RA calculated using the TJC28, SJC28, PtGA (VAS: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Weeks 2, 4 and Posttreatment Week 4

  16. Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by DAS28-CRP at Weeks 2, 4 and Posttreatment Week 4

    Low disease activity is defined as DAS28-CRP ≤ 3.2. DAS28 score was used to measure the participant's disease activity or assessments of RA calculated using the TJC28, SJC28, PtGA (VAS: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Weeks 2, 4 and Posttreatment Week 4

  17. Part B: Percentage of Participants Who Achieved Remission as Measured by CDAI at Weeks 2, 4 and Posttreatment Week 4

    Clinical remission is defined as CDAI ≤ 2.8. CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.

    Time frame: Weeks 2, 4 and Posttreatment Week 4

  18. Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by CDAI at Weeks 2, 4 and Posttreatment Week 4

    Low disease activity is defined as CDAI ≤ 10. CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.

    Time frame: Weeks 2, 4 and Posttreatment Week 4

  19. Part B: Percentage of Participants Who Achieved Remission as Measured by SDAI at Weeks 2, 4 and Posttreatment Week 4

    Clinical remission is defined as SDAI ≤ 3.3. SDAI is a composite measure that sums the TJC28, SJC28, PtGA, PhGA, and the CRP (in mg/dL). PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.

    Time frame: Weeks 2, 4 and Posttreatment Week 4

  20. Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by SDAI at Weeks 2, 4 and Posttreatment Week 4

    Low disease activity is defined as SDAI ≤ 11. SDAI is a composite measure that sums the TJC28, SJC28, PtGA, PhGA, and the CRP (in mg/dL). PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.

    Time frame: Weeks 2, 4 and Posttreatment Week 4

07

Results

Posted Sep 9, 2020

Participant flow

Participants were enrolled at 11 study sites in the United States. The first participant was screened on 26 January 2016. The last study visit occurred on 01 September 2016.

Participant flow — Overall Study
MilestoneCohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: PlaceboPart B: Tirabrutinib 20 mg QDPart B: Placebo
Started8282175
Completed8282165
Not completed000010
Withdrew: Randomized but never treated000010

Outcome measures

PrimaryPart A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to last dose (maximum: 7 days) plus 30 days
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsCohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: Placebo
Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)25.050.037.50
PrimaryPart A: Percentage of Participants With Treatment-Emergent Laboratory Abnormalities

A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment after the first dose of study drug and within 30 days after last study drug administration. Laboratory abnormalities without clinical significance were not recorded as AEs or serious AEs. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = potentially life threatening.

Time frame:
First dose date up to last dose (maximum: 7 days) plus 30 days
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
percentage of participantsCohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: Placebo
Hemoglobin Decreased25.0037.550.0
Neutrophils Decreased0000
White Blood Cells Decreased0000
Alanine Aminotransferase (ALT) Increased25.0025.00
Aspartate Aminotransferase (AST) Increased12.5025.00
Alkaline Phosphatase Increased0012.50
Amylase12.5000
Calcium Increased12.5000
Fasting Glucose Increased12.5000
Gamma-glutamyl Transferase (GGT) Increased25.0000
Glucose Increased12.5000
Phosphorus Decreased12.5000
Sodium Decreased050.000
Total Cholesterol Increased25.0012.5100.0
Triglycerides Increased25.0037.550.0
Magnesium Increased0000
Potassium Decreased0000
PrimaryPart A: Percentage of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
Time frame:
First dose date up to last dose (maximum: 7 days) plus 30 days
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
percentage of participantsCohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: Placebo
Part A: Percentage of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities0000
PrimaryPart A: Cmax: Maximum Observed Plasma Concentration of Tirabrutinib

Cmax is maximum observed concentration of drug in plasma.

Time frame:
Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Reported as:
Mean · nanogram per milliliter (ng/mL)
Part A: Cmax: Maximum Observed Plasma Concentration of Tirabrutinib
nanogram per milliliter (ng/mL)Cohort 1, Part A: Tirabrutinib 20 mg QDCohort 2, Part A: Tirabrutinib 10 mg BID
Day 133.8 ± 7.9416.2 ± 4.66
Day 756.4 ± 11.1932.3 ± 8.59
PrimaryPart A: Clast: Last Observed Quantifiable Plasma Concentration of Tirabrutinib

Clast is the last observed concentration of drug in plasma.

Time frame:
Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Reported as:
Mean · ng/mL
Part A: Clast: Last Observed Quantifiable Plasma Concentration of Tirabrutinib
ng/mLCohort 1, Part A: Tirabrutinib 20 mg QDCohort 2, Part A: Tirabrutinib 10 mg BID
Day 12.58 ± 1.3665.22 ± 1.729
Day 71.50 ± 0.5512.03 ± 0.756
PrimaryPart A: Tmax: Time (Observed Time Point) of Cmax of Tirabrutinib

Tmax is the time observed for the Cmax of tirabrutinib.

Time frame:
Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Reported as:
Median · hours
Part A: Tmax: Time (Observed Time Point) of Cmax of Tirabrutinib
hoursCohort 1, Part A: Tirabrutinib 20 mg QDCohort 2, Part A: Tirabrutinib 10 mg BID
Day 12.00 (1.50 to 4.00)3.00 (1.50 to 4.00)
Day 72.00 (1.50 to 3.00)2.00 (1.50 to 4.00)
PrimaryPart A: Tlast: Time (Observed Time Point) of Clast of Tirabrutinib

Tlast is the time observed for the Clast of tirabrutinib.

Time frame:
Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Reported as:
Median · hours
Part A: Tlast: Time (Observed Time Point) of Clast of Tirabrutinib
hoursCohort 1, Part A: Tirabrutinib 20 mg QDCohort 2, Part A: Tirabrutinib 10 mg BID
Day 123.92 (12.00 to 23.92)11.92 (11.92 to 12.00)
Day 730.00 (24.00 to 48.00)24.00 (18.00 to 36.00)
PrimaryPart A: AUCtau: Area Under the Plasma Concentration (AUC) Versus Time Curve Over the Dosing Interval of Tirabrutinib

AUC is concentration of drug over time (area under the plasma concentration versus time curve).

Time frame:
Cohorts 1 and 2, Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose relative to the morning dose
Reported as:
Mean · hours*nanogram per milliliter (h*ng/mL)
Part A: AUCtau: Area Under the Plasma Concentration (AUC) Versus Time Curve Over the Dosing Interval of Tirabrutinib
hours*nanogram per milliliter (h*ng/mL)Cohort 1, Part A: Tirabrutinib 20 mg QDCohort 2, Part A: Tirabrutinib 10 mg BID
Part A: AUCtau: Area Under the Plasma Concentration (AUC) Versus Time Curve Over the Dosing Interval of Tirabrutinib360.5 ± 97.49195.2 ± 44.43
PrimaryPart A: AUClast: AUC Versus Time Curve From Time Zero to the Last Quantifiable Concentration of Tirabrutinib

AUC is concentration of drug over time (area under the plasma concentration versus time curve).

Time frame:
Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
Reported as:
Mean · h*ng/mL
Part A: AUClast: AUC Versus Time Curve From Time Zero to the Last Quantifiable Concentration of Tirabrutinib
h*ng/mLCohort 1, Part A: Tirabrutinib 20 mg QDCohort 2, Part A: Tirabrutinib 10 mg BID
Day 1228.3 ± 89.96107.1 ± 27.54
Day 7377.8 ± 119.80245.5 ± 65.02
PrimaryPart B: Percentage of Participants Who Experienced TEAEs

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or Any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date up to last dose (maximum: 29 days) plus 30 days
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Experienced TEAEs
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Part B: Percentage of Participants Who Experienced TEAEs37.540.0
PrimaryPart B: Percentage of Participants With Treatment-Emergent Laboratory Abnormalities

A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment after the first dose of study drug and within 30 days after last study drug administration. Laboratory abnormalities without clinical significance were not recorded as AEs or serious AEs. Treatment-emergent laboratory abnormalities were graded per CTCAE, version 4.03 where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = potentially life threatening.

Time frame:
First dose date up to last dose (maximum: 29 days) plus 30 days
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Hemoglobin Decreased6.30
Neutrophils Decreased6.30
White Blood Cells Decreased6.30
Alanine Aminotransferase (ALT) Increased12.520.0
Fasting Glucose Increased12.520.0
Glucose Increased12.520.0
Magnesium Increased18.80
Potassium Decreased12.50
PrimaryPart B: Percentage of Participants With 12-Lead ECG Abnormalities
Time frame:
First dose date up to last dose (maximum: 29 days) plus 30 days
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With 12-Lead ECG Abnormalities
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Part B: Percentage of Participants With 12-Lead ECG Abnormalities00
SecondaryPart A: Change From Baseline in Percent Inhibition of CD63 Basophils at Days 1, 3, 5 and 7

The effect of tirabrutinib on biomarkers was assessed through the CD63 basophil activation test (BAT) FlowCast assay, which was used to measure the percentage of CD63+ basophils and percentage inhibition of CD63 induction relative to baseline. CD63+ % inhibition was calculated as 100 - CD63+ % baseline. Baseline defined as day 1 predose.

Time frame:
Days 1 and 7: Predose and 2, 6, 12, 24 hours postdose; Days 3 and 5: Predose and 2 hours postdose
Reported as:
Mean · percentage of Inhibition
Part A: Change From Baseline in Percent Inhibition of CD63 Basophils at Days 1, 3, 5 and 7
percentage of InhibitionCohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: Placebo
Day 1, Predose0 ± 00 ± 00 ± 00 ± 0
Day 1, 2 Hours Postdose17.189 ± 6.83060.272 ± 2.332619.557 ± 11.04793.568 ± 1.4734
Day 1, 6 Hours Postdose34.966 ± 15.64368.779 ± 9.910127.506 ± 16.07441.782 ± 6.3117
Day 1, 12 Hours Postdose——35.008 ± 24.1663-2.688 ± 16.7688
Day 1, 24 Hours Postdose33.305 ± 14.92485.604 ± 1.2275——
Day 3, Predose47.416 ± 17.04700.917 ± 11.428183.832 ± 10.1042-11.354 ± 16.5029
Day 3, 2 Hours Postdose73.972 ± 15.1658-0.842 ± 4.639590.187 ± 5.6699-13.641 ± 13.0667
Day 5, Predose55.680 ± 21.50182.779 ± 3.702383.380 ± 10.3976-2.271 ± 0.2060
Day 5, 2 Hours Postdose80.271 ± 16.8806-0.043 ± 2.306991.159 ± 7.4740-15.923 ± 11.5733
Day 7, Predose56.986 ± 20.39725.234 ± 0.875780.024 ± 11.03716.271 ± 7.9790
Day 7, 2 Hours Postdose79.910 ± 15.3155-2.831 ± 0.735888.032 ± 7.8750-0.978 ± 9.9380
Day 7, 6 Hours Postdose88.102 ± 11.6072-1.320 ± 8.177689.681 ± 7.0909-2.645 ± 6.3382
Day 7, 12 Hours Postdose——80.640 ± 10.0574-10.062 ± 13.2554
Day 7, 24 Hours Postdose52.017 ± 17.5829-0.046 ± 0.6432——
SecondaryPart A: Change From Baseline in Percent Bruton's Tyrosine Kinase (BTK) Occupancy at Days 1, 3, 5 and 7

BTK occupancy was assessed with the BTK occupancy assay, which was used to measure undetectable free BTK, normalized free BTK, normalized free BTK adjusted to baseline, and percentage BTK occupancy adjusted to baseline. % BTK occupancy adjusted was calculated as 100 \* (1 - normalized free BTK adjusted to baseline). Normalized free BTK was calculated as Free BTK / Total BTK. Baseline defined as day 1 predose.

Time frame:
Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose; Days 3 and 5: Predose and 2 hours postdose; Day 7: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, 120 hours postdose
Reported as:
Mean · percentage of BTK occupancy
Part A: Change From Baseline in Percent Bruton's Tyrosine Kinase (BTK) Occupancy at Days 1, 3, 5 and 7
percentage of BTK occupancyCohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: Placebo
Day 1, Predose0 ± 00 ± 0
Day 1, 0.5 Hour Postdose-2.765 ± 14.6036-4.686 ± 1.8358
Day 1, 1 Hour Postdose11.635 ± 17.8025-11.927 ± 8.4893
Day 1, 2 Hours Postdose55.250 ± 10.0230-8.959 ± 16.7122
Day 1, 3 Hours Postdose62.719 ± 7.7060-9.810 ± 18.8212
Day 1, 4 Hours Postdose66.790 ± 7.9494-16.597 ± 25.0492
Day 1, 6 Hours Postdose71.936 ± 8.3606-6.014 ± 19.5348
Day 1, 8 Hours Postdose75.350 ± 11.5216-16.584 ± 17.8202
Day 1, 12 Hours Postdose77.411 ± 8.69286.170 ± 12.7312
Day 1, 18 Hours Postdose81.187 ± 8.8687-2.261 ± 27.3338
Day 1, 24 Hours Postdose72.691 ± 10.8289-28.029 ± 10.1821
Day 3, Predose84.010 ± 8.4919-19.564 ± 20.3282
Day 3, 2 Hours Postdose90.606 ± 6.1066-35.206 ± 25.2258
Day 5, Predose70.841 ± 43.059625.095 ± 99.0827
Day 5, 2 Hours Postdose93.128 ± 4.0582-25.646 ± 17.6912
Day 7, Predose86.936 ± 6.4745-22.662 ± 23.6252
Day 7, 0.5 Hours Postdose87.013 ± 5.2426-23.284 ± 9.9539
Day 7, 1 Hour Postdose86.274 ± 6.0720-12.230 ± 6.6727
Day 7, 2 Hours Postdose92.651 ± 3.4603-34.573 ± 17.9620
Day 7, 3 Hours Postdose92.983 ± 2.1906-32.920 ± 20.1029
Day 7, 4 Hours Postdose90.070 ± 7.4086-37.253 ± 16.2208
Day 7, 6 Hours Postdose91.591 ± 7.7733-39.632 ± 13.1749
Day 7, 8 Hours Postdose92.789 ± 3.2221-31.144 ± 20.1974
Day 7, 12 Hours Postdose91.251 ± 6.0300-33.947 ± 16.3475
Day 7, 18 Hours Postdose85.209 ± 5.0694-34.408 ± 12.5471
Day 7, 24 Hours Postdose86.256 ± 6.5648-42.577 ± 17.2138
Day 7, 36 Hours Postdose71.963 ± 10.5550-43.574 ± 8.4952
Day 7, 48 Hours Postdose64.763 ± 14.3072-46.249 ± 24.2785
Day 7, 60 Hours Postdose57.431 ± 9.0638-15.465 ± 9.4556
Day 7, 72 Hours Postdose46.218 ± 14.3155-49.093 ± 21.4447
Day 7, 96 Hours Postdose24.922 ± 6.8700-41.721 ± 32.0255
Day 7, 120 Hours Postdose15.285 ± 9.4140-48.863 ± 20.7533
SecondaryPart B: Change From Baseline in Disease Activity Score for 28 Joint Counts (DAS28) Using C-Reactive Protein (CRP) at Weeks 2, 4 and Posttreatment Week 4

DAS28 score was used to measure the participant's disease activity or assessments of rheumatoid arthritis (RA) calculated using the tender joint counts (TJC) (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (PtGA) (visual analog scale: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · score on a scale
Part B: Change From Baseline in Disease Activity Score for 28 Joint Counts (DAS28) Using C-Reactive Protein (CRP) at Weeks 2, 4 and Posttreatment Week 4
score on a scalePart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline4.54 ± 1.7285.12 ± 1.576
Change from Baseline at Week 2-0.35 ± 0.821-0.28 ± 0.977
Change from Baseline at Week 4-0.45 ± 1.097-0.11 ± 0.612
Change from Baseline at Posttreatment Week 4-0.41 ± 1.208-0.05 ± 0.782
SecondaryPart B: Change From Baseline in Individual American College of Rheumatology (ACR) Component: Tender Joint Count (TJC) Based on 68 Joints (TJC68) at Weeks 2, 4 and Posttreatment Week 4

ACR TJC was an assessment of 68 joints. At each study visit, a joint evaluator assessed whether a particular joint was "tender" where presence of tenderness was scored as "1" and the absence of tenderness was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons. It was derived as the sum of all tender joints. The range for TJC68 was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · tender joint count
Part B: Change From Baseline in Individual American College of Rheumatology (ACR) Component: Tender Joint Count (TJC) Based on 68 Joints (TJC68) at Weeks 2, 4 and Posttreatment Week 4
tender joint countPart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline18.20 ± 14.45421.70 ± 12.656
Change from Baselline at Week 2-2.57 ± 6.666-1.17 ± 7.980
Change from Baselline at Week 4-6.69 ± 8.4320.01 ± 0.829
Change from Baselline at Posttreatment Week 4-3.13 ± 9.9681.11 ± 12.638
SecondaryPart B: Change From Baseline in Individual ACR Component: Swollen Joint Count (SJC) Based on 66 Joints (SJC66) at Weeks 2, 4 and Posttreatment Week 4

ACR SJC was an assessment of 66 joints. At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons. It was derived as the sum of all swollen joints. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week
Reported as:
Mean · swollen joint count
Part B: Change From Baseline in Individual ACR Component: Swollen Joint Count (SJC) Based on 66 Joints (SJC66) at Weeks 2, 4 and Posttreatment Week 4
swollen joint countPart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline12.70 ± 10.94412.04 ± 12.488
Change from Baseline at Week 2-4.13 ± 6.446-2.58 ± 9.910
Change from Baseline at Week 4-4.82 ± 7.586-2.23 ± 6.048
Change from Baseline at Posttreatment Week 4-3.07 ± 5.2721.53 ± 3.035
SecondaryPart B: Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4 and Posttreatment Week 4

SDAI is a composite measure that sums the TJC based on 28 joints (TJC28), SJC based on 28 joints (SJC28), PtGA, Physician's Global Assessment of Disease Activity (PhGA), and the CRP (in mg/dL). PtGA and PhGA assessed using Visual Analogue Scale (VAS) on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · score on a scale
Part B: Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4 and Posttreatment Week 4
score on a scalePart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline30.19 ± 20.28333.20 ± 19.061
Change from Baseline at Week 2-4.49 ± 11.786-5.20 ± 14.035
Change from Baseline at Week 4-6.84 ± 14.016-1.69 ± 5.439
Change from Baseline at Posttreatment Week 4-4.82 ± 14.349-1.16 ± 12.293
SecondaryPart B: Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4 and Posttreatment Week 4

CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · score on a scale
Part B: Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4 and Posttreatment Week 4
score on a scalePart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline29.63 ± 19.99431.96 ± 18.622
Change from Baseline at Week 2-4.44 ± 11.748-5.32 ± 13.264
Change from Baseline at Week 4-6.80 ± 13.925-2.02 ± 5.206
Change from Baseline at Posttreatment Week 4-4.73 ± 14.180-1.74 ± 11.562
SecondaryPart B: Change From Baseline in Individual ACR Component: Patient's Global Assessment of Disease Activity (PtGA) at Weeks 2, 4 and Posttreatment Week 4

PtGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A horizontal visual analog scale was used to provide the patient's overall assessment of how the arthritis is doing. A mark was placed on the horizontal line to assess the current arthritis disease activity. The lowest mark indicated 'no arthritis activity', and the highest mark indicated 'extremely active arthritis'. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · score on a scale
Part B: Change From Baseline in Individual ACR Component: Patient's Global Assessment of Disease Activity (PtGA) at Weeks 2, 4 and Posttreatment Week 4
score on a scalePart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline42 ± 27.463 ± 30.5
Change from Baseline at Week 2-10 ± 20.7-6 ± 17.6
Change from Baseline at Week 4-10 ± 22.1-10 ± 16.7
Change from Baseline at Posttreatment Week 4-4 ± 22.2-9 ± 17.8
SecondaryPart B: Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PhGA) at Weeks 2, 4 and Posttreatment Week 4

PhGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A horizontal visual analog scale was used to measure the physician's assessment of the patient's current disease activity. A mark was placed on the horizontal line to assess the disease activity (independent of the participant's self-assessment). The lowest mark indicated 'no disease activity', and the highest mark indicated 'maximum disease activity'. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · score on a scale
Part B: Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PhGA) at Weeks 2, 4 and Posttreatment Week 4
score on a scalePart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline39 ± 27.449 ± 15.5
Change from Baseline at Week 2-3 ± 23.5-16 ± 13.4
Change from Baseline at Week 4-8 ± 20.35 ± 14.9
Change from Baseline at Posttreatment Week 4-4 ± 22.7-3 ± 17.7
SecondaryPart B: Change From Baseline in Individual ACR Component: Patient's Global Assessment of Pain at Weeks 2, 4 and Posttreatment Week 4

The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A horizontal visual analog scale was used to assess the patient's current level of pain. A mark was placed on the horizontal line to assess the severity of pain. The lowest mark indicated 'no pain', and the highest mark indicated 'unbearable pain'. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · score on a scale
Part B: Change From Baseline in Individual ACR Component: Patient's Global Assessment of Pain at Weeks 2, 4 and Posttreatment Week 4
score on a scalePart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline39 ± 28.659 ± 28.9
Change from Baseline at Week 2-5 ± 26.2-6 ± 15.7
Change from Baseline at Week 4-9 ± 24.6-13 ± 16.2
Change from Baseline at Posttreatment Week 4-2 ± 22.9-11 ± 24.9
SecondaryPart B: Change From Baseline in the Health Assessment Questionnaire Disability Subscales (HAQ-DI) Score at Weeks 2, 4 and Posttreatment Week 4

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually administered by the participant. Responses in each functional category were collected as 0-3 \[0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · score on a scale
Part B: Change From Baseline in the Health Assessment Questionnaire Disability Subscales (HAQ-DI) Score at Weeks 2, 4 and Posttreatment Week 4
score on a scalePart B: Tirabrutinib 20 mg QDPart B: Placebo
Baseline1.063 ± 0.71301.650 ± 0.7776
Change from Baseline at Week 2-0.203 ± 0.5242-0.150 ± 0.2054
Change from Baseline at Week 4-0.234 ± 0.4492-0.100 ± 0.3687
Change from Baseline at Posttreatment Week 4-0.156 ± 0.35500.094 ± 0.1197
SecondaryPart B: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Weeks 2, 4 and Posttreatment Week 4

ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PhGA and PtGA assessed using VAS on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity); patient's pain assessment using VAS on a scale of 0-100 (0 indicating no pain and 100 indicating unbearable pain); HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 (0 and 3 indicating without difficulty and unable to do); high-sensitivity CRP (hsCRP).

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Weeks 2, 4 and Posttreatment Week 4
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Week 26.320.0
Week 418.80
Posttreatment Week 412.50
SecondaryPart B: Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) Response at Weeks 2, 4 and Posttreatment Week 4

ACR70 response is achieved when the participant has: ≥ 70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PhGA and PtGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; patient's pain assessment using VAS on a scale of 0-100 \[0 indicating no pain and 100 indicating unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP.

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) Response at Weeks 2, 4 and Posttreatment Week 4
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
At Week 200
At Week 46.30
At Posttreatment Week 400
SecondaryPart B: Hybrid ACR Improvement Response at Weeks 2, 4 and Posttreatment Week 4

Hybrid ACR evaluates the improvement in active RA by combining elements of the ACR20, ACR50, and ACR70 with a continuous score of the mean change in core set measures. The percentage improvement from baseline was computed in each of the components of the ACR. The average percent improvement was calculated and used with the participant's ACR20, ACR50, and ACR70 status to compute the hybrid ACR response, with a positive change indicating improvement.

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Mean · percent improvement
Part B: Hybrid ACR Improvement Response at Weeks 2, 4 and Posttreatment Week 4
percent improvementPart B: Tirabrutinib 20 mg QDPart B: Placebo
At Week 21.51 ± 30.6874.41 ± 25.410
At Week 43.29 ± 36.098-4.06 ± 14.459
At Posttreatment Week 40.44 ± 34.589-7.65 ± 20.606
SecondaryPart B: Percentage of Participants Who Achieved Remission as Measured by DAS28-CRP at Weeks 2, 4 and Posttreatment Week 4

Clinical remission is defined as DAS28-CRP \< 2.6. DAS28 score was used to measure the participant's disease activity or assessments of RA calculated using the TJC28, SJC28, PtGA (VAS: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Achieved Remission as Measured by DAS28-CRP at Weeks 2, 4 and Posttreatment Week 4
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Week 2: Remission based on DAS28-CRP (< 2.6)12.50
Week 4: Remission based on DAS28-CRP (< 2.6)12.50
Post Week 4: Remission based on DAS28-CRP (< 2.6)25.00
SecondaryPart B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by DAS28-CRP at Weeks 2, 4 and Posttreatment Week 4

Low disease activity is defined as DAS28-CRP ≤ 3.2. DAS28 score was used to measure the participant's disease activity or assessments of RA calculated using the TJC28, SJC28, PtGA (VAS: 0 = no disease activity to 100 = maximum disease activity) and CRP for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by DAS28-CRP at Weeks 2, 4 and Posttreatment Week 4
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Week 2: Low Disease Activity on DAS28-CRP (<= 3.2)18.820.0
Week 4: Low Disease Activity on DAS28-CRP (<= 3.2)12.520.0
Post Week4: Low Disease Activity DAS28-CRP (<=3.2)37.50
SecondaryPart B: Percentage of Participants Who Achieved Remission as Measured by CDAI at Weeks 2, 4 and Posttreatment Week 4

Clinical remission is defined as CDAI ≤ 2.8. CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Achieved Remission as Measured by CDAI at Weeks 2, 4 and Posttreatment Week 4
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Week 2: Remission based on CDAI (<= 2.8)12.50
Week 4: Remission based on CDAI (<= 2.8)6.30
Post Week 4: Remission based on CDAI (<= 2.8)6.30
SecondaryPart B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by CDAI at Weeks 2, 4 and Posttreatment Week 4

Low disease activity is defined as CDAI ≤ 10. CDAI is a composite measure that sums the TJC28, SJC28, PtGA, and PhGA. PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. CDAI total score range: 0 to 76. CDAI \<= 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity. A negative change from baseline indicates improvement.

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by CDAI at Weeks 2, 4 and Posttreatment Week 4
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Week 2: Low Disease Activity based on CDAI (<= 10)18.820.0
Week 4: Low Disease Activity based on CDAI (<= 10)18.820.0
Post Week 4: Low Disease Activity on CDAI (<= 10)31.320.0
SecondaryPart B: Percentage of Participants Who Achieved Remission as Measured by SDAI at Weeks 2, 4 and Posttreatment Week 4

Clinical remission is defined as SDAI ≤ 3.3. SDAI is a composite measure that sums the TJC28, SJC28, PtGA, PhGA, and the CRP (in mg/dL). PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Achieved Remission as Measured by SDAI at Weeks 2, 4 and Posttreatment Week 4
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Week 2: Remission based on SDAI (<= 3.3)12.50
Week 4: Remission based on SDAI (<= 3.3)6.30
Post Week 4: Remission based on SDAI (<= 3.3)6.30
SecondaryPart B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by SDAI at Weeks 2, 4 and Posttreatment Week 4

Low disease activity is defined as SDAI ≤ 11. SDAI is a composite measure that sums the TJC28, SJC28, PtGA, PhGA, and the CRP (in mg/dL). PtGA and PhGA assessed using VAS on a scale of 0-100 \[0 indicating no disease activity and 100 indicating maximum disease activity\]. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \> 26 = high disease activity. A negative change from baseline indicates improvement.

Time frame:
Weeks 2, 4 and Posttreatment Week 4
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Achieved Low Disease Activity Response as Measured by SDAI at Weeks 2, 4 and Posttreatment Week 4
percentage of participantsPart B: Tirabrutinib 20 mg QDPart B: Placebo
Week 2: Low Disease Activity based on SDAI (<= 11)25.020.0
Week 4: Low Disease Activity based on SDAI (<= 11)18.820.0
Post Week 4: Low Disease Activity on SDAI (<= 11)37.520.0

Adverse events

Collected over Adverse Events: Part A: First dose date up to last dose (maximum: 7 days) plus 30 days; Part B: First dose date up to last dose (maximum: 29 days) plus 30 days; All-Cause Mortality: First dose date up to approximately 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1, Part A: Tirabrutinib 20 mg QD0/8 (0%)0/8 (0%)2/8 (25%)
Cohort 2, Part A: Tirabrutinib 10 mg BID0/8 (0%)0/8 (0%)3/8 (37.5%)
Part B: Tirabrutinib 20 mg QD0/16 (0%)0/16 (0%)6/16 (37.5%)
All Placebo0/9 (0%)0/9 (0%)3/9 (33.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCohort 1, Part A: Tirabrutinib 20 mg QDCohort 2, Part A: Tirabrutinib 10 mg BIDPart B: Tirabrutinib 20 mg QDAll Placebo
Back painMusculoskeletal and connective tissue disorders1/82/80/160/9
Iron deficiency anaemiaBlood and lymphatic system disorders1/80/80/161/9
NauseaGastrointestinal disorders0/81/80/160/9
Muscle strainInjury, poisoning and procedural complications0/81/80/160/9
HeadacheNervous system disorders0/81/81/160/9
Abdominal tendernessGastrointestinal disorders0/80/80/161/9
Urinary tract infectionInfections and infestations0/80/80/161/9
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/80/81/161/9
Thyroid massEndocrine disorders0/80/81/160/9
ExtravasationGeneral disorders0/80/81/160/9

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: PlaceboPart B: Tirabrutinib 20 mg QDPart B: PlaceboTotal
Mean38 (30 to 44)37 (29 to 44)34 (22 to 45)38 (33 to 43)55 (38 to 64)52 (35 to 64)45.5 (22 to 64)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: PlaceboPart B: Tirabrutinib 20 mg QDPart B: PlaceboTotal
Female412013424
Male41623117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: PlaceboPart B: Tirabrutinib 20 mg QDPart B: PlaceboTotal
Hispanic or Latino82822224
Not Hispanic or Latino000014317
Unknown or Not Reported0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1, Part A: Tirabrutinib 20 mg QDCohort 1, Part A: PlaceboCohort 2, Part A: Tirabrutinib 10 mg BIDCohort 2, Part A: PlaceboPart B: Tirabrutinib 20 mg QDPart B: PlaceboTotal
Race — Black4001005
Race — White428116536
08

Study locations

9 sites
  • UC Davis Lawrence J. Ellison
    Sacramento, California 95817, United States
  • SeaView Research, Inc.
    Miami, Florida 33126, United States
  • Omega Research Consultants, LLC
    Orlando, Florida 32804, United States
  • Lovelace Scientific Resources, Inc.
    Venice, Florida 34292, United States
  • Center for Arthritis & Osteoporosis
    Elizabethtown, Kentucky 42701, United States
  • Justus J. Fiechtner, M.D., P.C.
    Lansing, Michigan 48910, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center of Reading, LLC
    Wyomissing, Pennsylvania 19610, United States
  • Arthritis & Osteoporosis Center of South Texas
    San Antonio, Texas 78232, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Sep 2016, 7 months.

Results were first posted in Sep 2020, 4 years after primary completion.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 7 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2015
First posted
Dec 10, 2015
StartActual
Jan 26, 2016
Primary completionActual
Sep 1, 2016
CompletionActual
Sep 1, 2016
Results first posted
Sep 9, 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02626026
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 10, 2015
Start date
Jan 26, 2016
Primary completion
Sep 1, 2016
Completion
Sep 1, 2016
Results posted
Sep 9, 2020
Last update
Sep 9, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirabrutinib

Start the discussion